Search Results 1331-1340 of 18701 for Relapse
This is a Phase 1b/2 open-label study to evaluate the safety/efficacy of MEDI-551 + MEDI0680 (AMP-514) in participants with relapsed or refractory ...
Mayo Clinic to offer CAR T-cell therapy for relapsed non-Hodgkin lymphoma featured. Cancer. Mayo Clinic to offer CAR T-cell therapy for relapsed non-Hodgkin ...
This phase II trial is studying the side effects of and how well alisertib works in treating young patients with relapsed or refractory solid tumors or leukemia ...
Participants with non-squamous NSCLC: has relapsed from or is refractory to standard treatment or for which no standard treatment is available. Participants ...
This is a Phase 1b/2 open-label study to evaluate the safety/efficacy of MEDI-551 + MEDI0680 (AMP-514) in participants with relapsed or refractory aggressive B- ...
... relapsed/refractory Non-Hodgkin's lymphomas or advanced solid tumors. An Investigational Immuno-therapy Safety and Effectiveness Study of Nivolumab in ...
This medicine will not cure MS, but it may slow some of the disabling effects and decrease the number of relapses of the disease. This medicine is to be ...
... relapse rates, readmisson rates (including admission to outside institutions), and chemical dependency treatment initiation and completion rates. We seek to ...
Also, to improve disease control by decreasing the number of spinal relapses for patients who achieve a complete response (CR) or partial response (PR) and ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your donation powers the future of medicine and helps save lives.